A Bold Leap for Global HIV Prevention: Lenacapavir Agreement Signed

Thrilled to announce that we’ve officially signed the agreement for Lenacapavir with UNITAID, CHAI, and Wits RHI. Together, we are making Lenacapavir, a twice-yearly HIV prevention injection available at just US$40 per year, accelerating access to this life-saving medicine across 120 low- and middle-income countries by 2027.

Deepak Sapra, CEO – API and Services at Dr. Reddy’s, on why this matters:

"Our partnership for Lenacapavir is a significant step in our mission to enhance global patient access and affordability to innovative treatment in the fight against HIV. The development and planned supply of a high-quality, affordable generic version of Lenacapavir represents a crucial advancement in HIV prevention. This collaboration brings together our scientific and market expertise with our partners’ technical, financial, and regulatory strengths. It reinforces our commitment to serve underserved populations, aligned with our ambitious goal to impact 1.5 billion patients by 2030, globally."

Representing Dr. Reddy’s today was a moment of immense pride. This achievement is the result of relentless belief, bold decisions (some irrational, some inspired!), and the unwavering commitment of a team that has championed public health access, from the early days of COVID to today’s global stage. To everyone who’s poured their heart into this journey: this recognition belongs to you!

Learn more about this landmark agreement: https://lnkd.in/dJ7vBBEx